Gram Research analysis shows that an engineered protein lacking tryptophan reduced stomach cancer tumor size by 64% in mice compared to normal protein, according to a 2026 study. The specially designed protein, created through genetic engineering and produced in yeast, successfully starved cancer cells of an amino acid they need to grow. While this proof-of-concept research is promising, it has only been tested in animals so far, and human clinical trials would be necessary before this approach could help cancer patients.
Scientists created a special protein that removes tryptophan, an amino acid that cancer cells need to grow. In laboratory tests with mice, this engineered protein reduced tumor size by 64% compared to normal protein. The research suggests that starving cancer cells of specific nutrients through specially designed foods could become a new way to help treat cancer alongside traditional therapies. This proof-of-concept study opens doors for developing medical foods that work with the body’s natural processes to slow tumor growth.
Key Statistics
A 2026 research article published in the Chinese Journal of Biotechnology found that mice fed a tryptophan-depleted engineered protein showed a 64% reduction in stomach cancer tumor weight compared to mice eating complete protein (P<0.001).
According to the 2026 study, the engineered tryptophan-depleted protein contained only 0.35 micrograms of tryptophan per gram after purification, successfully removing 99.9% of this amino acid that cancer cells require.
The research demonstrated that targeting amino acid metabolism through engineered dietary proteins reduced tumor growth significantly in a gastric adenocarcinoma xenograft model, establishing a novel framework for adjuvant cancer therapy.
The Quick Take
- What they studied: Whether removing tryptophan (a building block protein needs) from food could slow cancer growth in living organisms
- Who participated: Laboratory mice with human stomach cancer tumors implanted in them (no human participants in this study)
- Key finding: Mice eating the tryptophan-depleted protein had 64% smaller tumors than mice eating normal protein, with highly significant results (P<0.001)
- What it means for you: This is early-stage research showing promise for a new approach to cancer treatment, but it’s only been tested in mice so far. It may eventually lead to special medical foods that help cancer patients, but human trials would be needed first
The Research Details
Researchers used protein engineering, a technique where scientists modify the building blocks of proteins, to create a new type of protein missing tryptophan. They used baker’s yeast (Pichia pastoris) as a biological factory to produce this engineered protein. The protein was based on human serum albumin, a natural protein found in blood, with one specific tryptophan removed and replaced with a similar amino acid.
After creating the protein, they purified it using advanced filtering and separation techniques to ensure it contained almost no tryptophan (only 0.35 micrograms per gram). They then tested this protein in mice with stomach cancer tumors to see if a diet low in tryptophan would slow cancer growth compared to mice eating normal protein.
This approach is called ‘amino acid restriction therapy’, the idea that cancer cells depend heavily on certain nutrients, so removing those nutrients might starve the cancer while the body adapts better.
This research design is important because it bridges the gap between laboratory science and real-world application. Rather than just showing that tryptophan restriction works in test tubes, the researchers created an actual food-based intervention that could theoretically be given to patients. The use of protein engineering makes this practical, instead of asking patients to avoid all tryptophan-containing foods (which would be difficult), a single engineered protein could provide the same benefit.
This is a well-designed proof-of-concept study with clear methodology and strong results. The use of HPLC-MS/MS analysis (a gold-standard technique) confirms the protein actually contains minimal tryptophan. The statistical significance (P<0.001) indicates the results are very unlikely due to chance. However, this is animal research only, results in mice don’t always translate to humans. The study doesn’t specify sample size for the animal groups, which is a minor limitation. This is published research but represents early-stage development rather than clinical evidence.
What the Results Show
The main finding was dramatic: mice fed the tryptophan-depleted protein diet showed 64% reduction in tumor weight compared to control mice eating complete protein. This difference was highly statistically significant (P<0.001), meaning there’s less than a 0.1% chance this result happened by random variation.
The engineered protein successfully reduced tryptophan content to just 0.35 micrograms per gram, essentially removing the nutrient the researchers targeted. This confirms the protein engineering approach worked as intended and that the protein could be reliably manufactured.
The results suggest that cancer cells in these mice were indeed dependent on tryptophan for growth. By restricting this amino acid through diet, the researchers were able to slow tumor progression significantly. This supports the theory that targeting specific amino acid metabolism could be a viable cancer treatment strategy.
The study demonstrates that engineered proteins can be successfully produced using yeast expression systems, which is important for future manufacturing at scale. The purification methods used (hollow fiber membrane ultrafiltration and liquid chromatography) proved effective at removing tryptophan while maintaining protein function. The research establishes a framework for developing other engineered dietary proteins targeting different amino acids, potentially useful for various cancer types.
This research builds on growing evidence that amino acid restriction can suppress tumor growth. Previous studies showed tryptophan restriction works in cell cultures and theoretical models, but this is among the first to demonstrate it in a living organism using an engineered food protein. The 64% tumor reduction is substantial compared to other dietary intervention studies in similar models. This work advances the field by showing that amino acid restriction can be delivered practically through engineered foods rather than requiring patients to follow restrictive diets.
This study was conducted only in mice with implanted human cancer cells, results may not translate directly to humans with naturally occurring cancer. The study doesn’t report how many mice were used in each group or provide details about survival rates, only tumor weight reduction. There’s no information about side effects or whether the diet affected normal body functions. The research tested only one cancer type (gastric adenocarcinoma) and one amino acid (tryptophan), so results may not apply to other cancers. This is proof-of-concept research, not clinical evidence, so human trials would be necessary before any medical application.
The Bottom Line
This research is too early-stage to recommend for patients. It shows promise for future development of medical foods that could help cancer treatment, but human clinical trials are needed first. Current cancer patients should continue following their oncologist’s recommendations and not attempt tryptophan restriction diets without medical supervision, as this could cause nutritional problems.
Cancer researchers and oncologists should follow this work as it represents a novel approach to adjuvant (supportive) cancer therapy. Biotechnology companies developing medical foods should note this framework. Patients with cancer may eventually benefit, but only after extensive human testing. People without cancer should not attempt tryptophan restriction, as tryptophan is essential for health.
This is fundamental research with a long development timeline. If human trials begin soon, it could take 5-10 years before any engineered protein becomes available as a medical food. Realistic expectations: this represents a promising direction, not an immediate solution.
Frequently Asked Questions
Can I eat less tryptophan to prevent or treat cancer?
This research is only in early animal testing stages. Attempting tryptophan restriction without medical supervision could cause nutritional deficiencies, as tryptophan is essential for health. Wait for human clinical trials before considering any dietary changes for cancer prevention or treatment.
How does removing tryptophan help fight cancer?
Cancer cells depend heavily on tryptophan to grow and divide. By removing this amino acid, researchers essentially starved the cancer cells in mice, reducing tumor size by 64%. The approach targets cancer’s specific nutritional needs rather than harming healthy cells.
When will this engineered protein be available as a cancer treatment?
This is early-stage research published in 2026. Human clinical trials would need to occur first, which typically takes 5-10 years. If successful, the engineered protein might eventually become available as a specialized medical food to support cancer treatment.
Does this work for all types of cancer?
This study only tested stomach cancer in mice. Different cancers may respond differently to tryptophan restriction. Researchers would need to test other cancer types separately before knowing if this approach works broadly.
What are the risks of eating a tryptophan-depleted diet?
Tryptophan is essential for making serotonin, supporting immune function, and other vital processes. Long-term tryptophan restriction could cause mood problems, weakened immunity, and nutritional deficiencies. This is why medical supervision would be critical if this ever becomes a treatment.
Want to Apply This Research?
- For future cancer patients using such a medical food, track weekly tumor markers (if available through medical testing) and body weight to monitor both treatment efficacy and nutritional status
- Once available, users could log daily intake of the engineered protein product and correlate it with medical imaging results or biomarker tests to monitor response
- Long-term tracking would involve regular medical appointments with imaging studies, blood work monitoring amino acid levels, and quality-of-life assessments to ensure the intervention is working without causing nutritional deficiencies
This research represents early-stage laboratory and animal studies only. It has not been tested in humans and should not be used to guide personal medical decisions. Tryptophan is an essential amino acid necessary for human health, and attempting to restrict it without medical supervision could cause serious nutritional deficiencies. Anyone with cancer should work with their oncology team on evidence-based treatment plans. This article is for educational purposes and does not constitute medical advice. Consult with a healthcare provider before making any dietary changes related to cancer prevention or treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
